Avecho licenses TPM for use in cancer drugs
Filed with ASX · · 3 pages · English
• Avecho has today signed a licensing and development agreement with the Arthur Group LLC, entering a strategic partnership for the development of a series of leading cancer drugs with TPM®, replacing the adverse solvents or surfactants normally required. • The agreement includes rights to five separate oncology products, representing a combined US market of US $2.92 billion. • Under the terms of
Avecho Biotechnology Limited on 6ix
In the deck
Earlier from Avecho Biotechnology
- AVE commences manufacturing for Phase III trial
- Results of Entitlement Offer
- March 2023 Quarterly Activities Report & Appendix 4C
- Investor Presentation
- Prospectus
Later from Avecho Biotechnology
- USPTO allows new TPM manufacturing patent
- AVE adds TPM cannabinoid gummies to portfolio
- AVE CBD capsule passes two-year stability milestone
- June 2023 Quarterly Activities Report & Appendix 4C
- Voluntary Suspension
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology